Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Blood

Volumn 100, Issue 3, 2002, Pages 755-760

  Kröger, Nicolaus ^a,b,c   Schwerdtfeger, Rainer ^a,b,c   Kiehl, Michael ^a,b,c   Sayer, Herbert Gottfried ^a,b,c   Renges, Helmut ^a,b,c   Zabelina, Tatjana ^a,b,c   Fehse, Boris ^a,b,c   Tögel, Florian ^a,b,c   Wittkowsky, Georg ^a,b,c   Kuse, Rolf ^a,b,c   Zander, Axel Rolf ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; FLUCONAZOLE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; OFLOXACIN; PENTAMIDINE; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ALLOGRAFT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTIOUS COMPLICATION; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG TOXICITY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 0036682491     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0131     Document Type: Article

References (21)

1. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case matched study from the European Group for Blood and Marrow Transplantation
2. Donor lymphocyte infusion for relapsed multiple myeloma after allogeneic stem cell transplantation: Predictive factors for response and long term outcome
3. Graft versus myeloma effect: Proof of a principle
4. Polymerase chain reaction based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
5. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
6. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
7. Total marrow irradiation, busulfan, and cyclophosphamide for allografting in multiple myeloma
8. Engraftment of allogeneic hematopoietic progenitor cell with purine analog-containing chemotherapy: Harnessing graft versus leukemia effect without myeloablative therapy
9. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases
10. Hematopoietic cell transplantation in older patients with hematological malignancies: Replacing high-dose cytotoxic therapy with graft versus tumor effects
11. 1994 Consensus Conference on acute GvHD grading
12. Regimen related toxicity in patients undergoing bone marrow transplantation
13. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation
14. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
15. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors
16. Total therapy with tandem transplants from newly diagnosed multiple myeloma
17. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
18. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma
19. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
20. Single versus double transplantation in myeloma: A prospective randomized trial of the Inter Groupe Francais du Myeloma (IFM)
21. High response rate in refractory and poor risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions